01—Abstract
Summary
Summary of the 10-Q filed August 8, 2024. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) reported second-quarter 2024 results for the three months ended June 30, 2024, with total income and other revenues of $537.3 milliona, roughly flat versus $538.2 million a year earlier.
Net income attributable to Royalty Pharma plc was $102.0 millionb, or $0.23 per diluted Class A share, compared with $227.6 million, or $0.50, in the second quarter of 2023. The decline was driven mainly by a $212.4 million provision for changes in expected cash flows and credit losses, and by a $47.1 million loss on equity securities. For the first six months, net income attributable to Royalty Pharma plc was $106.8 million, down from $568.4 million, largely because the prior-year period included a $475.0 million Zavzpret milestone payment and non-recurring interest income.
Cash position and funding strengthened during the period. Cash and cash equivalents rose to $1.76 billionc at June 30, 2024, from $477.0 million at year-end 2023, after the company issued $1.5 billion of senior unsecured notes in June 2024 and generated $1.32 billion of operating cash flow in the first half. Total long-term debt was $7.60 billion carrying value against $7.8 billion of principal.
The company spent $814.7 milliond on acquisitions of financial royalty assets in the first six months and expanded its Cytokinetics funding collaboration, with up to $575 million in commitments. The filing also highlights Portfolio Receipts of $608.0 million in the quarter, up 11.6% from $544.6 million, and Vertex's cystic fibrosis franchise as the largest royalty source, at 36% of second-quarter total income and other revenues. Subsequent to quarter end, the filing notes FDA approval of Voranigo, for which the company agreed to pay $905 million upfront.
02—Key points
Key Highlights
- Total income and other revenues were $537.3 million in Q2 2024, essentially flat versus $538.2 million in Q2 2023.
- Net income attributable to Royalty Pharma plc fell to $102.0 million ($0.23 per diluted share) from $227.6 million ($0.50) a year earlier.
- A $212.4 million provision for changes in expected cash flows and credit losses in Q2 2024 weighed on operating income, which was $269.6 million versus $248.8 million.
- Portfolio Receipts rose 11.6% to $608.0 million in Q2 2024, led by the cystic fibrosis franchise, Trelegy and Evrysdi.
- Issued $1.5 billion of senior unsecured notes in June 2024; cash and cash equivalents increased to $1.76 billion from $477.0 million at December 31, 2023.
- Long-term debt rose to $7.60 billion, and $350 million remained available under Cytokinetics Funding Commitments at June 30, 2024.
- Repurchased 3.1 million Class A shares for about $84.4 million in Q2 2024, with $610.8 million remaining under the authorization.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 8, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $537.27M$538.20M | −0.2% |
| R&D Expenses | $500K$500K | 0.0% |
| Operating Expenses | $267.64M$289.36M | −7.5% |
| Operating Income | $269.63M$248.84M | +8.4% |
| Net Income | $102.00M$227.63M | −55.2% |
| EPS (Basic) | $0.23$0.51 | −54.9% |
| EPS (Diluted) | $0.23$0.50 | −54.0% |
| Shares Outstanding (Basic) | 451.02M450.40M | +0.1% |
| Shares Outstanding (Diluted) | 596.91M605.86M | −1.5% |
05—Questions
Frequently Asked Questions
Why did net income fall so sharply compared with the prior year?
Net income attributable to Royalty Pharma plc decreased to $102.0 million in Q2 2024 from $227.6 million in Q2 2023. The filing attributes the change mainly to a $212.4 million non-cash provision for changes in expected cash flows and credit losses, compared with $241.2 million in the prior-year quarter, and to a $47.1 million loss on equity securities versus a $41.3 million gain. For the first six months, the prior-year period also included a $475.0 million Zavzpret milestone and $153.6 million of non-recurring interest income.
How did the company fund its recent royalty acquisitions?
In June 2024, the company issued $1.5 billion of senior unsecured notes, with a weighted average coupon of 5.48%. Net cash provided by financing activities was $944.6 million for the first six months, primarily from those note proceeds. Operating cash flow was $1.32 billion for the same period, and $814.7 million was used for acquisitions of financial royalty assets.
What drove the cash flow from operations and Portfolio Receipts?
Portfolio Receipts were $608.0 million in Q2 2024, up 11.6% from $544.6 million. The filing cites the continued U.S. performance of Trikafta, strong uptake of Kaftrio outside the United States, Trelegy demand, and Evrysdi growth from incremental royalties acquired in Q4 2023. Net cash provided by operating activities for the first six months decreased to $1.32 billion from $1.64 billion, mainly because the prior-year period included the $475.0 million Zavzpret milestone.
What is the significance of the Voranigo royalty acquisition?
The company agreed in May 2024 to acquire a royalty interest in Voranigo (vorasidenib) from Agios Pharmaceuticals for an upfront payment of $905 million, contingent on FDA approval. The filing states that the FDA approved Voranigo in August 2024. Following approval, the company will receive a 15% royalty on annual U.S. net sales up to $1 billion and a 12% royalty on sales above $1 billion.
How concentrated is the royalty portfolio?
Vertex's cystic fibrosis franchise was the largest source of royalty income, accounting for 36% of total income and other revenues in Q2 2024 and 37% for the first six months. The filing notes that the top five product franchises accounted for 64% of Royalty Receipts in the first six months of 2024, and that the company's portfolio is not fully diversified by geography or other criteria.
06—Continue